ENSC
NASDAQEnsysce Biosciences Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$0.52-0.00 (-0.76%)
03:45 PM07:45 PM
News · 26 weeks31-50%
2026-04-192026-10-11
Mix2190d
- SEC Filings9(43%)
- Market8(38%)
- Other2(10%)
- Insider2(10%)
Latest news
25 items- SECAmendment: SEC Form 8-K/A filed by Ensysce Biosciences Inc.8-K/A - Ensysce Biosciences, Inc. (0001716947) (Filer)
- SECSEC Form 8-K filed by Ensysce Biosciences Inc.8-K - Ensysce Biosciences, Inc. (0001716947) (Filer)
- NEWSEnsysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA~ Submission to the UK MHRA for review marks critical step towards initiating a Phase 2 Study with CY200 ~ SAN DIEGO, CA / ACCESS Newswire / September 24, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), today announced the submission of the protocol for a Phase 2a clinical study of CY200, the Company's newest drug candidate from the newly acquired Cy Biopharma Inc.This landmark milestone involved the submission of protocol CYBIO_001 entitled "A Phase 2A, Multicenter, Randomised, Double-blin
- NEWSEnsysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug RegulationSAN DIEGO, CA / ACCESS Newswire / September 15, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), hosted a symposium at PainWeek 2026. The Symposium was attended by more than 320 pain management professionals. Dr. Jeff Gudin provided background on the Ensysce novel program to provide safer opioids for severe pain as well as a substantial background on complex pain, specifically Complex Regional Pain Syndrome Type 1 (CRPS). Dr. Richard Langford also outlined the novel approach to CRPS, the platform t
- NEWSEnsysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic DrugsSAN DIEGO, CA / ACCESS Newswire / September 14, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), today announced that Richard Langford, Chief Medical Officer of Cy Biopharma, has been selected to present in person at the U.S. Food and Drug Administration's ("FDA") public hearing, "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs," being held today, Monday, September 14, 2026 at the FDA's White Oak Campus in Silver Spring, Maryland.Dr. Langford is among a limited group of sta
- NEWSEnsysce Biosciences Announces Upcoming Conference and Industry Event ParticipationSAN DIEGO, CA / ACCESS Newswire / September 2, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), today announced its participation in the following upcoming investors conferences and industry events.2026 Cantor Global Healthcare Conference being held Wednesday, September 9th to Saturday, September 12th at the Waldorf Astoria in New York City. The Company will host a presentation at 9:10am ET on Friday, September 10th.The H.C. Wainwright 28th Annual Global Investment Conference being held Monday, Sep
- NEWSEnsysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study~ ~ The Second Study Fully Enrolled for Breakthrough Therapy-Designated, First-in-Class Opioid Designed to Protect Against Oral Overdose ~ ~ SAN DIEGO, CA / ACCESS Newswire / August 31, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on complex pain, and advancing next-generation pain and central nervous system therapeutics designed to reduce abuse and overdose risk, today announced completion of enrollment in the final stage of the PF614-MPAR-102 clinical study. The study evaluated its novel MPAR® (Multi-Pill Abuse Resistance) overdose-protection tech
- SECEnsysce Biosciences Inc. filed SEC Form 8-K: Other Events8-K - Ensysce Biosciences, Inc. (0001716947) (Filer)
- SECEnsysce Biosciences Inc. filed SEC Form 8-K: Other Events8-K - Ensysce Biosciences, Inc. (0001716947) (Filer)
- SECSEC Form D filed by Ensysce Biosciences Inc.D - Ensysce Biosciences, Inc. (0001716947) (Filer)
- NEWSEnsysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium~Major symposium to highlight breakthrough innovations in severe pain and Complex Regional Pain Syndrome (CRPS) ~~Discussions to feature a first-in-class approach to neural reset and novel chemical safety switch technology ~ SAN DIEGO, CA / ACCESS Newswire / August 20, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on complex pain, today announced that it will host an educational symposium at PAINWeek 2026, entitled A New Era in Pain Therapeutics.The symposium will present a vision for the future of pain management-one that introduces an
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Ensysce Biosciences Inc.SCHEDULE 13D/A - Ensysce Biosciences, Inc. (0001716947) (Subject)
- INSIDERDirector Gower Bob G bought $444,169 worth of shares (908,614 units at $0.49), increasing direct ownership by 11,182% to 916,740 units (SEC Form 4)4 - Ensysce Biosciences, Inc. (0001716947) (Issuer)
- SECSEC Form 10-Q filed by Ensysce Biosciences Inc.10-Q - Ensysce Biosciences, Inc. (0001716947) (Filer)
- SECEnsysce Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Ensysce Biosciences, Inc. (0001716947) (Filer)
- NEWSEnsysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business HighlightsAcquisition of Cy Biopharma Completed, Adding CY200 for Complex Regional Pain SyndromeUp to $77 million in new funding with the acquisition of Cy BiopharmaCompany to host a Corporate Update Call on Tuesday, August 18, 2026, at 11:00 a.m. ET SAN DIEGO, CA / ACCESS Newswire / August 13, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on complex pain, today reported financial and operational results for the second quarter ended June 30, 2026.On August 6, 2026, we completed the acquisition of Cy Biopharma, Inc. ("Cy Biopharma") with private
- INSIDERSEC Form 3 filed by new insider Morrison James William3 - Ensysce Biosciences, Inc. (0001716947) (Issuer)
- SECAmendment: Ensysce Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K/A - Ensysce Biosciences, Inc. (0001716947) (Filer)
- PRWhy Investors Are Watching These Healthcare MoversDENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) -- (https://247mnn.com/) – ClearOne (NASDAQ:CLRO), NeOnc Technologies (NASDAQ:NTHI), Iovance Biotherapeutics (NASDAQ:IOVA), and Ensysce Biosciences (NASDAQ:ENSC) are covered in today’s roundup. ClearOne Advances Toward Neurotechnology Transformation ClearOne (NASDAQ:CLRO) continues moving closer to completing its planned transformation into a neurotechnology company as new SEC filings remove several key uncertainties surrounding its pending acquisition of Cortigent, a wholly owned subsidiary of Vivani Medical (NASDAQ:VANI), which was first announced on July 2, as investors continue tracking milestones that could reshape the company's future. Clear
- SECEnsysce Biosciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Regulation FD Disclosure8-K - Ensysce Biosciences, Inc. (0001716947) (Filer)
- NEWSEnsysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private FinancingAcquisition includes clinical-stage neuroplastogenic therapy with U.S. FDA Orphan Drug Designation for the treatment of Complex Regional Pain Syndrome (CRPS)Up to $77 million in private financing consisting of $21.5 million in private placement financing at initial close plus $17.1 million of Cy Biopharma's cash and cash equivalents from a pre-acquisition convertible note financing and up to $38.6 million upon achievement of clinical trial milestonePro forma cash expected to fund CY200 through Phase 2 proof-of-concept data and into registrational development SAN DIEGO, CA / ACCESS Newswire / August 6, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") today announced
- SECSEC Form 8-K filed by Ensysce Biosciences Inc.8-K - Ensysce Biosciences, Inc. (0001716947) (Filer)
- NEWSEnsysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal GrantFunds Advance FDA-Designated Breakthrough Therapy First-in-Class Opioid with Oral Overdose-Protection SAN DIEGO, CA / ACCESS Newswire / July 14, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics engineered to minimize abuse and overdose risk, today announced receipt of a Notice of Award for $5.3 million from the National Institutes on Drug Abuse (NIDA)1 to support the development of its novel MPAR® (Multi-Pill Abuse Resistance) overdose-protection technology, and the lead agent, PF614-MPAR. This marks the third consecutive year of NIDA funding under this
- SECSEC Form EFFECT filed by Ensysce Biosciences Inc.EFFECT - Ensysce Biosciences, Inc. (0001716947) (Filer)
- NEWSEnsysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study~ ~ Advances First-in-Class, Breakthrough Therapy-Designated Opioid Engineered to Protect Against Oral Overdose ~ ~ SAN DIEGO, CA / ACCESS Newswire / June 26, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics engineered to minimize abuse and overdose risk, today announced initiation of the final stage of the PF614-MPAR-102 clinical study. The study is evaluating its novel MPAR® (Multi-Pill Abuse Resistance) overdose-protection technology.Rather than relying on traditional abuse‑deterrent technologies, PF614‑MPAR is engineered to provide active protection
ENSC FAQ
6 questionsWhat does Ensysce Biosciences Inc. do?
Ensysce Biosciences, Inc., a clinical-stage biotech company, engages in developing various prescription drugs. The company is developing tamper-proof opioids using Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms. Its products treat severe pain and assist in preventing deaths caused by opioid abuse. The company is headquartered in La Jolla, California.Where does ENSC stock trade?
Ensysce Biosciences Inc. (ENSC) is listed on NASDAQ.What sector and industry is ENSC in?
Ensysce Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ENSC?
Ensysce Biosciences Inc. has had 1 recent analyst action on file. The most recent action was from Lake Street: Buy with a $400.00 price target on 2021-11-30. Recent price targets cluster around $400.00.What companies are similar to ENSC?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ENSC side-by-side with any of them on Quantisnow.How can I track ENSC on Quantisnow?
Quantisnow aggregates Ensysce Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ENSC to receive live email and push alerts on every new disclosure.